NCT06789159View on ClinicalTrials.gov

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

October 1, 2028

Study Completion Date

October 1, 2028

Conditions
Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma RelapsedEpstein-Barr Virus (EBV) Infection
Interventions
DRUG

VK-2019

VK-2019 will be administered daily starting on day 1 of cycle 1 (D1C1). Dose cohort A will dose at 600 mg dose cohort B 1200 mg and dose cohort C 1800 mg. Treatment cycles will repeat every 28 days , in the absence of disease progression or unacceptable toxicity.

Trial Locations (1)

19107

RECRUITING

Honickman Center, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

The Wistar Institute

OTHER

lead

Thomas Jefferson University

OTHER

NCT06789159 - A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL) | Biotech Hunter | Biotech Hunter